Liver Cancer Newswire (Page 2)

Comprehensive Real-Time News Feed for Liver Cancer. (Page 2)

Results 21 - 40 of 2,500 in Liver Cancer

  1. Combined therapy improves survival for patients with liver cancer who are not suitable for surgeryRead the original story w/Photo

    Wednesday Sep 10 | Medical News Today

    ... survival was 20.3 months for patients with intermediate stage HCC and 8.6 months for patients with advanced liver cancer . These final results were better than the preliminary data released in 2010. Led by Prof Pierce Chow, Senior Consultant Surgeon ...

    Comment?

  2. Deschutes County prosecutor denied liver transplantRead the original story w/Photo

    Tuesday Sep 9 | Local TV Station KTVZ

    Dan Reesor, a prosecutor with the Deschutes County District Attorney's Office, was diagnosed with liver cancer earlier this year. His doctor told him without a liver transplant, he will die.

    Comment?

  3. Exelixis'Read the original story w/Photo

    Tuesday Sep 9 | Seeking Alpha

    ... MET VEGF inhibitor. And we have ongoing pivotal trials in thyroid cancer, prostate cancer, renal cancer and liver cancer. With the data from COMET-1 last week, we have de-prioritized prostate cancer and are really focused on our next key milestone ...

    Comment?

  4. Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015...Read the original story

    Tuesday Sep 9 | Freshnews

    "We continued to advance the bavituximab clinical program on multiple fronts with the major focus on executing the SUNRISE Phase III trial which is progressing well with the initiation of new global clinical sites bringing the total participating sites to over 130. In addition, our collaborator at UT Southwestern recently completed enrollment in an important liver cancer study opening the door for data from this study as well as other bavituximab clinical trials to be presented over the coming months," said Steven W. King, president and chief executive officer of Peregrine.

    Comment?

  5. Beer pairing dinner to raise money for locals battling cancerRead the original story w/Photo

    Tuesday Sep 9 | Williams

    ... when she's already going through what she is." At about the same time, Reynolds began his second bout with liver cancer. Reynolds is a finger-style guitarist who has played professionally since 1969. He's played at Cruiser's since before the ...

    Comment?

  6. Argon Medical Devices, Inc. Acquires US BiopsyRead the original story

    Tuesday Sep 9 | Sys-Con Media

    ... liver disease and the prevalence of liver diseases such as hepatitis C, non-alcoholic fatty liver disease, and liver cancer are on the rise. Additionally, up to 25% of Americans may have non-alcoholic fatty liver disease. These patients may require ...

    Comment?

  7. GenSpera Receives Patent On Prodrug Targeted For Prostate CancerRead the original story

    Tuesday Sep 9 | BioSpace

    ... in Phase II clinical trials for glioblastoma (brain cancer) patients and for hepatocellular carcinoma (liver cancer) patients after sorafenib (NexavarA ) therapy. GenSpera currently owns or licenses 13 issued patents overall with 10 relating to ...

    Comment?

  8. Biotech News Alert: GenSpera (OTCQB:GNSZ) Receives Patent on Prodrug Targeted for Prostate CancerRead the original story

    Tuesday Sep 9 | InvestorIdeas.com

    ... in Phase II clinical trials for glioblastoma (brain cancer) patients and for hepatocellular carcinoma (liver cancer) patients after sorafenib (Nexavar ) therapy. GenSpera currently owns or licenses 13 issued patents overall with 10 relating to ...

    Comment?

  9. Neurovive Pharmaceutical: NeuroVive signs USD 150 m agreement with...Read the original story

    Tuesday Sep 9 | Information Technology

    ... B infection can cause chronic liver disease, which increases a patient's risk of death from liver cirrhosis and liver cancer. Estimates from the Centers for Disease Control and Prevention (CDC) indicate that up to 350 million people globally may be ...

    Comment?

  10. NeuroVive Pharmaceutical AB, Oncore Sign $150 Million Hepatitis B PactRead the original story

    Tuesday Sep 9 | BioSpace

    ... B infection can cause chronic liver disease, which increases a patient's risk of death from liver cirrhosis and liver cancer. Estimates from the Centers for Disease Control and Prevention (CDC) indicate that up to 350 million people globally may be ...

    Comment?

  11. Oncore Licenses Second-Generation Cyclophilin Inhibitors From...Read the original story

    Tuesday Sep 9 | BioSpace

    ... B infection can cause chronic liver disease, which increases a patient's risk of death from liver cirrhosis and liver cancer. Estimates from the Centers for Disease Control and Prevention (CDC) indicate that up to 350 million people globally may be ...

    Comment?

  12. Researchers examine whether new drug offers added benefit for patients with chronic HCVRead the original story w/Photo

    Tuesday Sep 9 | Medical News

    ... becomes chronic, cirrhosis can develop and liver function progressively deteriorates. Moreover, the risk of liver cancer (hepatocellular carcinoma, HCC ) increases. Simeprevir aims to inhibit the reproduction of HCV. Experts assume that if no ...

    Comment?

  13. OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors...Read the original story

    Tuesday Sep 9 | Hispanic Business

    ... B infection can cause chronic liver disease, which increases a patient's risk of death from liver cirrhosis and liver cancer. Estimates from the (CDC) indicate that up to 350 million people globally may be chronically infected with hepatitis B and, ...

    Comment?

  14. NeuroVive signs USD 150 m agreement with OnCore BioPharma for the...Read the original story

    Monday Sep 8 | Hispanic Business

    ... B infection can cause chronic liver disease, which increases a patient's risk of death from liver cirrhosis and liver cancer. Estimates from the (CDC) indicate that up to 350 million people globally may be chronically infected with Hepatitis B and, ...

    Comment?

  15. MELD increases long-term survival in liver cancer patientsRead the original story

    Monday Sep 8 | GastroHep.com

    A study in this month's Clinical Gastroenterology & Hepatology reports increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for End-stage Liver Disease score. Assignment of Model for End-stage Liver Disease exception points to patients with hepatocellular carcinoma who fall within Milan criteria, which began in 2003, increases their priority on liver transplantation waitlists.

    Comment?

  16. Prediabetes Linked to Higher Risk of Cancer, Study FindsRead the original story w/Photo

    Monday Sep 8 | LiveScience

    ... for liver, endometrial, stomach and colon cancer people with prediabetes were about twice as likely to develop liver cancer , 60 percent more likely to develop endometrial cancer and 50 percent more likely to develop stomach or colon cancer, than ...

    Comment?

  17. Simeprevir in hepatitis C: Added benefit for certain patientsRead the original story w/Photo

    Monday Sep 8 | Science Daily

    ... becomes chronic, cirrhosis can develop and liver function progressively deteriorates. Moreover, the risk of liver cancer (hepatocellular carcinoma, HCC) increases. Simeprevir aims to inhibit the reproduction of HCV. Experts assume that if no viruses ...

    Comment?

  18. Blueprint Medicines Presents Positive Data On BLU-554 For Hepatocellular CarcinomaRead the original story

    Monday Sep 8 | BioSpace

    Results demonstrate in vivo efficacy, including sustained tumor regression and complete remissions in mice with tumors that represent a genomically defined subset of human HCC. The oral presentation was given at the International Liver Cancer Association 8th Annual Conference in "Our preclinical data are early promising proof for the potential clinical benefit of targeting a defined subset of HCC patients based on the genetic profile of their cancers," said , PhD, MBA, chief scientific officer of Blueprint Medicines.

    Comment?

  19. GenSpera Presents Mipsagargin (G-202) HCC Clinical Trial Update At ConferenceRead the original story

    Monday Sep 8 | BioSpace

    ... developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8th International Liver Cancer Association (ILCA) Conference on ...

    Comment?

  20. Sirtex Medical Inc. Expands Business Into BrazilRead the original story w/Photo

    Monday Sep 8 | Manufacturing.net

    Sirtex Medical Inc. , a subsidiary of Sirtex Medical Limited, a leading manufacturer of targeted liver cancer therapies, announced today the expansion of its business in Latin America. Sirtex's SIR-Spheres microspheres are now available to treat inoperable liver tumors in Brazil.

    Comment?